NT-3 attenuates functional and structural disorders in sensory nerves of galactose-fed rats.
The present study investigated the effect of NT-3, a neurotrophin expressed in nerve and skeletal muscle, on myelinated fiber disorders of galactose-fed rats. Adult, female Sprague-Dawley rats were fed diets containing complete micronutrient supplements and either 0% D-galactose (control) or 40% D-galactose. Treated controls received 20 mg/kg NT-3 and treated galactose-fed rats received 1, 5, or 20 mg/kg NT-3 three times per week by subcutaneous injections. After 2 months, sciatic and saphenous sensory nerve conduction velocity (SNCV) and sciatic motor nerve conduction velocity (MNCV) were measured and the sciatic, sural, peroneal and saphenous nerves and dorsal and ventral roots processed for light microscopy. Treatment of control animals with NT-3 had no effect on any functional or structural parameter. Compared to control values, galactose feeding induced a sensory and motor nerve conduction deficit and a reduction in axonal caliber. Treatment with 5 and 20 mg/kg NT-3 ameliorated deficits in sciatic and saphenous SNCV in galactose-fed rats but had no effect on the MNCV deficit. NT-3 treatment also attenuated the decrease in mean axonal caliber in the dorsal root and sural nerve but not in the saphenous nerve, ventral root and peroneal nerve. These observations show that NT-3 can selectively attenuate the sensory conduction deficit of galactose neuropathy in a dose-dependent manner that depends only in part on restoration of axonal caliber of large-fiber sensory neurons.
Mizisin
A P
AP
Department of Pathology, University of California, San Diego, the Veterans Administration Medical Center, La Jolla 92093-0612, USA.
Kalichman
M W
MW
Bache
M
M
Dines
K C
KC
DiStefano
P S
PS
D000818:Animals; D001369:Axons / Q000187:drug effects / Q000502:physiology; D005260:Female; D005527:Food, Fortified; D005690:Galactose / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity*; D006801:Humans; D007279:Injections, Subcutaneous; D009046:Motor Neurons / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology; D009431:Neural Conduction / Q000187:drug effects* / Q000502:physiology; D009475:Neurons, Afferent / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D020933:Neurotrophin 3; D010543:Peroneal Nerve / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012584:Sciatic Nerve / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D013126:Spinal Nerve Roots / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D013127:Spinal Nerves / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology
D009414:Nerve Growth Factors; D020933:Neurotrophin 3; D011994:Recombinant Proteins; D005690:Galactose